Clinical studies recruiting near Wollongong

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
EARLY_Phase 1 · Wollongong Hospital · Radiopharm Theranostics, Ltd · NCT06824155 The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Phase 1/Phase 2 · Wollongong Private Hospital · Lin BioScience, Inc · NCT05756322 Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Phase 2 · ADARx Clinical Site · ADARx Pharmaceuticals, Inc. · NCT06989359 Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Ag
Phase 1 · Wollongong Hospital /ID# 265625 · AbbVie · NCT06896916 A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
Phase 1/Phase 2 · Wollongong Hospital · Radiopharm Theranostics, Ltd · NCT07259213 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S
Phase 1/Phase 2 · Wollongong Hospital · ModernaTX, Inc. · NCT05533697 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · Local Institution - 0017 · Celgene · NCT05519085 Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · Cancer Care Wollongong · Avenzo Therapeutics, Inc. · NCT05867251 Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesop
Phase 3 · Wollongong Hospital · Daiichi Sankyo · NCT06731478 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · Research Site · AstraZeneca · NCT06692738 A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/
Phase 1 · Investigational Site Number : 0360001 · Sanofi · NCT06630806 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 · Wollongong Hospital · BeOne Medicines · NCT07492641 A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
NA · South Coast Urology · Rivermark Medical · NCT06849258 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 Guideline Oriented Approach To Lipid Lowering In Asia-Pacific
NA · Illawarra Shoalhaven Local Health District · Stephen Nicholls · NCT05325034 Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic N
Phase 3 · Research Site · AstraZeneca · NCT07291037 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · Research Site · AstraZeneca · NCT06627647 Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Ch
Phase 2 · Wollongong and Shoalhaven District Memorial Hospital · Australasian Gastro-Intestinal Trials Group · NCT06441747 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108
Phase 3 · Wollongong Hospital ( Site 0453) · Merck Sharp & Dohme LLC · NCT06997497 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Dar
Phase 3 · Wollongong Hospital · Janssen Research & Development, LLC · NCT05552222 The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study
NA · Wollongong Hospital · University of Leicester · NCT04204915 A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Phase 1/Phase 2 · GSK Investigational Site · GlaxoSmithKline · NCT06796907 FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
Phase 2 · Wollongong Hospital · The George Institute · NCT06409364 A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Phase 1/Phase 2 · Cancer Care Wollongong Pty Limited · LaNova Medicines Limited · NCT06868199 Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
NA · Wollongong Hospital · The University of Queensland · NCT03573089 AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Phase 1/Phase 2 · Research Site · AstraZeneca · NCT06106945 A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i
Phase 3 · Wollongong Hospital · Incyte Corporation · NCT07284849 Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2 · Wollongong Hospital · Canadian Cancer Trials Group · NCT05180097 A Study of LM-350 in Subjects With Advanced Solid Tumours
Phase 1/Phase 2 · Cancer Care Wollongong Pty Limited · LaNova Medicines Limited · NCT07112222 Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · Cancer Care Wollongong · Mirati Therapeutics Inc. · NCT04613596

Look up another city

Look up another condition